Rimegepant is an orally-administered small-molecule calcitonin gene receptor peptide ( CGRP) antagonist developed by Bristol-Myers Squibb. The drug was launched with the permission of the US Food and Drug Administration( FDA) in March 2020 for the treatment of acute migraine with or without aura in adults. Unlike triptans, rimegepant has no vasoconstrictive properties, but has better safety and tolerability, which displays good prospect for its clinical application.